Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530010 · ClinicalTrials.gov registry record
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A clinical trial of Liver Cancer, sponsored by Northwestern University.
- Completed
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT00530010: Completed study of Liver Cancer, sponsored by Northwestern University.
NCT00530010 is a study of Liver Cancer that has completed, run by Northwestern University. The registered enrollment target is 500 participants, above the 442-participant average among 78 other Liver Cancer trials with a reported enrollment target (13% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00530010, a study of Liver Cancer, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. PURPOSE: This phase II trial is studying how well radiolabeled glass beads work in treating patients with liver cancer that cannot be removed by surgery.
Primary Outcome
Proportion of patients completing scheduled treatment plan
Conditions Studied
Interventions
- RADIATION yttrium Y 90 glass microspheres
Study Locations (1)
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2004-12 |
| Est. Completion | 2022-03-08 |
What the finished NCT00530010 record still lists
NCT00530010 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 442-participant average among 78 other Liver Cancer trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which yttrium Y 90 glass microspheres is the first listed.
NCT00530010 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00530010 about?
NCT00530010 is a clinical study titled "Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery". RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. PURPOSE: This phase II trial is studying how we...
What is the current status of trial NCT00530010?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2004-12. Estimated completion is 2022-03-08.
What conditions does trial NCT00530010 study?
This clinical trial studies the following conditions: Liver Cancer.
What interventions are being tested in trial NCT00530010?
The interventions under investigation include: yttrium Y 90 glass microspheres (RADIATION).
Who is sponsoring clinical trial NCT00530010?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00530010 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00530010's enrollment target sits among peer trials
500 11th of 78 higher than 67 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Study of CBCT for IGRT in Cancer Patients
RECRUITING · NA
-
Collection of Blood From Patients With Cancer
RECRUITING
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
RECRUITING · NA
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia